Glycemic Variability of Combination Therapies in T2DM

A Multicenter Study to Evaluate Efficacy and Safety

Glycemic Variability of Combination Therapies in T2DM

A multicenter study to evaluate efficacy and safety

Inclusion Criteria:

• Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg/day) and SGLT-2 inhibitor.

Exclusion Criteria:

• History of acute or chronic metabolic acidosis
• Moderate to severe renal impairment (eGFR < 45 mL/min/1.73m²)
• Severe hepatic impairment
• History of heart failure (NYHA Class III/IV)